Breaking Finance News

JP Morgan downgraded Teva Pharmaceutical (NYSE:TEVA) from Neutral to Underweight in a report released today.

JP Morgan has downgraded Teva Pharmaceutical (NYSE:TEVA) from Neutral to Underweight in a report released on 11/13/2017.

Yesterday Teva Pharmaceutical (NYSE:TEVA) traded 2.03% higher at $11.66. The company’s 50-day moving average is $16.31 and its 200-day moving average is $24.86. The last closing price is down -45.33% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. 1,425,193 shares of the stock traded hands, down from an average trading volume of 25,252,700

See Chart Below

Teva Pharmaceutical (NYSE:TEVA)

Teva Pharmaceutical has a 52 week low of $13.26 and a 52 week high of $44.12 The company’s market cap is currently $0.

In addition to JP Morgan reporting its target price, a total of 22 firms have reported on the stock. The consensus target price is $72.82 with 10 firms rating the stock a strong buy, 9 firms rating the stock a buy, 6 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Teva Pharmaceutical (NYSE:TEVA)

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.